Onohara Takeshi, Hisatome Ichiro, Kurata Yasutaka, Li Peili, Notsu Tomomi, Morikawa Kumi, Otani Naoyuki, Yoshida Akio, Iitsuka Kazuhiko, Kato Masaru, Miake Junichiro, Ninomiya Haruaki, Higaki Katsumi, Shirayoshi Yasuaki, Nishihara Takashi, Itoh Toshiyuki, Nakamura Yoshinobu, Nishimura Motonobu
Division of Organ Regeneration Surgery, Tottori University Faculty of Medicine, Yonago, Japan.
Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Tottori University Graduate School of Medical Science, Nishichou 36-1, Yonago, Japan.
J Arrhythm. 2017 Jun;33(3):226-233. doi: 10.1016/j.joa.2016.09.003. Epub 2016 Oct 19.
Pilsicainide, classified as a relatively selective Na channel blocker, also has an inhibitory action on the rapidly-activating delayed-rectifier K current ( ) through human ether-a-go-go-related gene (hERG) channels. We studied the effects of chronic exposure to pilsicainide on the expression of wild-type (WT) hERG proteins and WT-hERG channel currents, as well as on the expression of mutant hERG proteins, in a heterologous expression system.
HEK293 cells stably expressing WT or mutant hERG proteins were subjected to Western blotting, immunofluorescence microscopy and patch-clamp experiments.
Acute exposure to pilsicainide at 0.03-10 μM influenced neither the expression of WT-hERG proteins nor WT-hERG channel currents. Chronic treatment with 0.03-10 μM pilsicainide for 48 h, however, increased the expression of WT-hERG proteins and channel currents in a concentration-dependent manner. Chronic treatment with 3 μM pilsicainide for 48 h delayed degradation of WT-hERG proteins and increased the channels expressed on the plasma membrane. A cell membrane-impermeant pilsicainide derivative did not influence the expression of WT-hERG, indicating that pilsicainide stabilized the protein inside the cell. Pilsicainide did not influence phosphorylation of Akt (protein kinase B) or expression of heat shock protein families such as HSF-1, hsp70 and hsp90. E4031, a chemical chaperone for hERG, abolished the pilsicainide effect on hERG. Chronic treatment with pilsicainide could also increase the protein expression of trafficking-defective mutant hERG, G601S and R752W.
Pilsicainide penetrates the plasma membrane, stabilizes WT-hERG proteins by acting as a chemical chaperone, and enhances WT-hERG channel currents. This mechanism could also be applicable to modulations of certain mutant-hERG proteins.
吡西卡尼被归类为相对选择性的钠通道阻滞剂,它还通过人醚 - 去极化相关基因(hERG)通道对快速激活延迟整流钾电流( )具有抑制作用。我们在异源表达系统中研究了长期暴露于吡西卡尼对野生型(WT)hERG蛋白表达、WT - hERG通道电流以及突变型hERG蛋白表达的影响。
对稳定表达WT或突变型hERG蛋白的HEK293细胞进行蛋白质免疫印迹、免疫荧光显微镜检查和膜片钳实验。
急性暴露于0.03 - 10 μM的吡西卡尼既不影响WT - hERG蛋白的表达,也不影响WT - hERG通道电流。然而,用0.03 - 10 μM吡西卡尼进行48小时的慢性处理,以浓度依赖的方式增加了WT - hERG蛋白的表达和通道电流。用3 μM吡西卡尼进行48小时的慢性处理延迟了WT - hERG蛋白的降解,并增加了质膜上表达的通道。一种细胞膜不透性的吡西卡尼衍生物不影响WT - hERG的表达,表明吡西卡尼稳定了细胞内的蛋白质。吡西卡尼不影响Akt(蛋白激酶B)的磷酸化或热休克蛋白家族如HSF - 1、hsp70和hsp90的表达。hERG的化学伴侣E4031消除了吡西卡尼对hERG的作用。用吡西卡尼进行慢性处理也可以增加转运缺陷型突变体hERG、G601S和R752W的蛋白表达。
吡西卡尼穿透质膜,作为化学伴侣稳定WT - hERG蛋白,并增强WT - hERG通道电流。这种机制也可能适用于某些突变型hERG蛋白的调节。